About US
Contact us
-
AstraZeneca secures ODD from FDA for saracatinib to treat IPFAstraZeneca has secured orphan drug designation (ODD) from the US Food and Drug Administration (FDA) for its potential new medicine, saracatinib, to treat a type of lung disease known as idiopathic p2019/3/18
-
Deerfield commits $100m for translational research deal with HarvardHealthcare investment firm Deerfield Management has formed a strategic partnership with Harvard University for research and development (R&D) focused on new translational medicine. Deerfield has2019/3/15
-
Common antifungal drug offers hope for cystic fibrosis treatmentNew research from the University of Illinois and the University of Iowa has showed that a common antifungal drug, called amphotericin, could help cystic fibrosis (CF) patients fight chronic lung infe2019/3/15
-
US Senate invites pharmacy benefit managers to testify on drug pricingThe US Senate Finance Committee has invited executives from five major pharmacy benefit managers (PBMs) to testify about the rising prescription medicine costs in the country. Senate chairman Chuck G2019/3/14
-
Irish scientists secure EU funding for Parkinson’s research projectThe Royal College of Surgeons in Ireland (RCSI) has been awarded a grant for a new research project that seeks to improve scientific understanding of Parkinson’s disease and lead to the development o2019/3/14
-
Pfizer’s biosimilar to Roche’s Herceptin receives approval from FDAPfizer has secured approval from the US Food and Drug Administration (FDA) for its drug Trazimera (trastuzumab-qyyp), a biosimilar medicine to Roche’s Herceptin (trastuzumab). The approval covers ind2019/3/13
-
Brussels aims to attract UK pharma business post-BrexitThe Brussels Capital Region has launched a major campaign to attract UK-based pharmaceutical and life sciences organisations after Brexit. Pharmaceutical businesses based in the British region will r2019/3/13
-
GeNeuro announces positive results from two-year study of MS drugSwiss biopharma company GeNeuro has announced tgat its two-year Phase IIb study of temelimab in multiple sclerosis (MS) confirmed the results from a previous 48-week CHANGE-MS trial where the drug ha2019/3/12
-
UK prioritises transport of medical products in no-deal Brexit scenarioDespite continued attempts to reach a deal acceptable to Parliament in order for the UK to leave the European Union (EU) with a deal on 29 March, various UK Government departments have listed critica2019/3/12
-
Now that Lilly has a cheaper generic Humalog, will Novo Nordisk and Sanofi follow?Caught by an outcry over high insulin prices, Eli Lilly recently unveiled anauthorized generic version of its Humalog insulin at half the price of the original brand. Now the question is: Will Sanofi2019/3/11